Tenaya Therapeutics

top of page

ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations

CEO Faraz Ali walks us through the data, which included six patients, and sets the table for a future update on a gene therapy program for hypertrophic cardiomyopathy that will be announced before the end of the quarter. Coverage brought to you by

Company News

May 15

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations

Follow BiotechTV

Sponsors

Sponsor Spotlight